Clinical and Translational Oncology

, Volume 17, Issue 10, pp 835–839 | Cite as

Metabolic syndrome is an independent prognostic factor for endometrial adenocarcinoma

  • J. Ni
  • T. Zhu
  • L. Zhao
  • F. Che
  • Y. Chen
  • H. ShouEmail author
  • A. YuEmail author
Brief Research Article



To study the association between metabolic syndrome (MS) and the prognosis of patients with endometrial adenocarcinoma.


A total of 385 patients with endometrial adenocarcinoma in the Department of Gynecologic Oncology, at the Zhejiang Cancer Hospital in China, between January 2001 and December 2008 were chosen. The deadline for the completion of follow-up was December 2013. The overall survival (OS) of the patients with MS was analyzed by the Kaplan–Meier method. Various clinical characteristics (e.g., clinical and surgical stage, vascular invasion, histological grade, tumor size, age at start of the first treatment, and lymphatic metastasis) related to the prognosis of endometrial adenocarcinoma were also evaluated.


A univariate analysis demonstrated that the OS rate of the patients with endometrial adenocarcinoma with MS was significantly worse than that of the patients without MS for all 385 patients (P = 0.001). Multivariate Cox proportional hazards regression analyses showed that stage (P = 0.001), lymphatic metastasis (P = 0.021), and MS (P = 0.049) were independent prognostic factors for endometrial adenocarcinoma. Furthermore, statistical analyses demonstrated that MS was closely related to stage (P = 0.021), grade (P = 0.022), vascular invasion (P = 0.044), tumor size (P = 0.035), and lymphatic metastasis (P = 0.014) but not with age at start of the first treatment (P = 0.188). Finally, according to the univariate analysis of the OS rate of 129 cases of endometrial adenocarcinoma with MS, stage (P = 0.001), vascular invasion (P = 0.049), tumor size >2 cm (P = 0.028), lymphatic metastasis (P = 0.002), and CA19-9 value >37 U/m (P = 0.002) all showed significantly low P values for OS.


Metabolic syndrome is an independent prognostic factor for endometrial adenocarcinoma.


Endometrial adenocarcinoma Metabolic syndrome Prognosis 



This work was supported by the Medical Science Project of Zhejiang Province (No. 2013KYB045).

Conflict of interest

All authors confirm that they have no conflicts of interest.


  1. 1.
    Furberg AS, Thune I. Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort. Int J Cancer. 2003;104(6):669–76.CrossRefPubMedGoogle Scholar
  2. 2.
    Kim JJ, Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod Med. 2010;28(1):81–90.CrossRefPubMedGoogle Scholar
  3. 3.
    Bjørge T, Engeland A, Tretli S, Weiderpass E. Body size in relation to cancer of the uterine corpus in 1 million Norwegian women. Int J Cancer. 2007;120(2):378–83.CrossRefPubMedGoogle Scholar
  4. 4.
    Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607–18.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Friedenreich CM, Biel RK, Lau DC, Csizmadi I, Coumeya KS, Magliocco AM, et al. Case–control study of the metabolic syndrome and metabolic risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2011;20:2384–95.CrossRefPubMedGoogle Scholar
  6. 6.
    Rosato V, Zucchetto A, Bosetti C, Dal Maso L, Montella M, Pelucchi C, et al. Metabolic syndrome and endometrial cancer risk. Ann Oncol. 2011;22:884–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402–11.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Alberti KG, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.CrossRefPubMedGoogle Scholar
  9. 9.
    Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol. 2000;13(3):295–308.CrossRefPubMedGoogle Scholar
  10. 10.
    Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Emons G, Fleckenstein G, Hinney B, Huschmand A, Heyl W. Hormonal interactions in endometrial cancer. Endocr Relat Cancer. 2000;7(4):227–42.CrossRefPubMedGoogle Scholar
  12. 12.
    Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24(29):4783–91.CrossRefPubMedGoogle Scholar
  13. 13.
    Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhou JR, Blackburn GL, Walker WA. Symposium introduction: metabolic syndrome and the onset of cancer. Am J Clin Nutr. 2007;86(3):s817–9.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am J Pathol. 2006;169(5):1505–22.CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Lund Haheim L, Wisløff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol. 2006;164(8):769–74.CrossRefPubMedGoogle Scholar
  17. 17.
    StürmerT Buring JE, Lee IM, Gaziano JM, Glynn RJ. Metabolic abnormalities and risk for colorectal cancer in the physicians’ health study. Cancer Epidemiol Biomarkers Prev. 2006;15(12):2391–7.CrossRefPubMedCentralPubMedGoogle Scholar
  18. 18.
    Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Tjønneland A, et al. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer. 2007;14(3):755–67.CrossRefPubMedGoogle Scholar
  19. 19.
    Bjørge T, Stocks T, Lukanova A, Tretli S, Selmer R, Manjer J, et al. Metabolic syndrome and endometrial carcinoma. Am J Epidemiol. 2010;171(8):892–902.CrossRefPubMedGoogle Scholar
  20. 20.
    ShouHF Ni J, Zhu T, Chen JH, Zhang X, Xu XX, et al. Association between endometrial cancer and metabolic syndrome. Zhonghua Fu Chan Ke Za Zhi. 2010;45(2):128–31.PubMedGoogle Scholar
  21. 21.
    Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, et al. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(4):921–9.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Cust AE, Allen NE, Rinaldi S, Dossus L, Friedenreich C, Olsen A, et al. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007;120(12):2656–64.CrossRefPubMedGoogle Scholar
  23. 23.
    Lukanova A, Zeleniuch-Jacquotte A, Lundin E, Micheli A, Arslan AA, Rinaldi S, et al. Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer. 2004;108(2):262–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91.CrossRefPubMedGoogle Scholar
  25. 25.
    Rapp K, Schroeder J, Klenk J, Ulmer H, Concin H, Diem G, et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia. 2006;49(5):945–52.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2015

Authors and Affiliations

  1. 1.Department of Gynecologic OncologyZhejiang Cancer HospitalHangzhouPeople’s Republic of China

Personalised recommendations